Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Senate Finance Drug Pricing Bill Would Have ‘Negligible’ Impact, Analyst Predicts

Executive Summary

Now that US drug pricing reform seems inevitable, the Senate bill offers the most positive outcome for industry, Bernstein analyst Ronny Gal suggests. 

You may also be interested in...



Senate Drug Pricing Bill Lowers Manufacturer Discounts In Part D Catastrophic Phase

Revised bill released by the US Senate Finance Committee adjusts the manufacturer discount program in Medicare Part D and includes new provisions aimed at easing beneficiary cost sharing obligations.

Trump's International Pricing Proposal Being Revised To Adopt ‘Most Favored Nation’ Policy – Azar

HHS Secretary Alex Azar says that reshaping Administration’s upcoming proposed rule would drive Medicare Part B drug prices even lower than previously projected. As Part B drug costs are being blamed for higher premiums, the policy revisions are at OMB, but plan would reemerge as "a notice of proposed rulemaking if that comes out,” Azar said.

US House Drug Pricing Bill Amended To Target Launch Prices, Set For Swift Advance

House Speaker Pelosi’s amended HR 3 expands scope of targeted drugs, adds manufacturer transparency requirements ahead of dual markups and a hearing on 17 October.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS141275

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel